tradingkey.logo

MaxCyte Inc

MXCT
1.630USD
+0.130+8.67%
收盘 12/22, 16:00美东报价延迟15分钟
173.83M总市值
亏损市盈率 TTM

MaxCyte Inc

1.630
+0.130+8.67%

关于 MaxCyte Inc 公司

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.

MaxCyte Inc简介

公司代码MXCT
公司名称MaxCyte Inc
上市日期Mar 29, 2016
CEOMasoud (Maher)
员工数量114
证券类型Ordinary Share
年结日Mar 29
公司地址9713 Key West Avenue,
城市ROCKVILLE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编20850
电话13015175556
网址https://www.maxcyte.com/
公司代码MXCT
上市日期Mar 29, 2016
CEOMasoud (Maher)

MaxCyte Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
398.33K
+33.52%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
230.58K
+53.13%
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
+75.00%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
+20.58%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+136.71%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
50.00K
--
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Non-Executive Independent Director
Non-Executive Independent Director
39.89K
+86.70%
Ms. Cynthia L. Collins
Ms. Cynthia L. Collins
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William W. (Will) Brooke, J.D.
Mr. William W. (Will) Brooke, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Patrick J. Balthrop
Mr. Patrick J. Balthrop
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
398.33K
+33.52%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
230.58K
+53.13%
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
+75.00%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
+20.58%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+136.71%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
50.00K
--

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
业务USD
名称
营收
占比
Product sales
5.27M
61.94%
Licenses
2.93M
34.42%
other
310.00K
3.64%
由于公司未披露,未能获取相关数据
业务
地区
业务USD
名称
营收
占比
Product sales
5.27M
61.94%
Licenses
2.93M
34.42%
other
310.00K
3.64%

股东统计

更新时间: 12月1日 周一
更新时间: 12月1日 周一
持股股东
股东类型
持股股东
持股股东
占比
Cadian Capital Management LP
7.71%
Mirabella Financial Services LLP
7.69%
BlackRock Institutional Trust Company, N.A.
7.54%
The Vanguard Group, Inc.
5.24%
River Global Investors LLP
5.15%
其他
66.67%
持股股东
持股股东
占比
Cadian Capital Management LP
7.71%
Mirabella Financial Services LLP
7.69%
BlackRock Institutional Trust Company, N.A.
7.54%
The Vanguard Group, Inc.
5.24%
River Global Investors LLP
5.15%
其他
66.67%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
24.33%
Investment Advisor
22.61%
Hedge Fund
17.87%
Research Firm
4.86%
Private Equity
4.73%
Individual Investor
1.74%
Venture Capital
0.36%
Bank and Trust
0.19%
Pension Fund
0.15%
其他
23.16%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
287
82.96M
77.85%
-17.02M
2025Q2
296
78.80M
73.92%
-18.62M
2025Q1
308
82.56M
77.59%
-14.89M
2024Q4
308
80.42M
75.91%
-14.30M
2024Q3
300
80.65M
76.72%
-18.62M
2024Q2
297
80.25M
76.66%
-17.97M
2024Q1
302
79.09M
75.86%
-22.52M
2023Q4
303
79.97M
77.01%
-14.24M
2023Q3
292
77.05M
74.47%
-17.27M
2023Q2
284
79.82M
77.43%
-11.81M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Cadian Capital Management LP
8.91M
8.36%
-1.11M
-11.10%
Jun 30, 2025
Mirabella Financial Services LLP
6.60M
6.19%
+2.90M
+78.38%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.21M
7.7%
+793.69K
+10.70%
Jun 30, 2025
The Vanguard Group, Inc.
5.60M
5.25%
+36.02K
+0.65%
Jun 30, 2025
River Global Investors LLP
3.25M
3.05%
+1.19M
+57.73%
Dec 31, 2024
Vitruvian Partners LLP
5.04M
4.73%
--
--
Jun 30, 2025
Morgan Stanley & Co. LLC
4.23M
3.97%
+795.36K
+23.12%
Jun 30, 2025
Mudita Advisors LLP
3.37M
3.16%
+42.25K
+1.27%
Jun 30, 2025
AXA Investment Managers UK Ltd.
2.20M
2.07%
+1.22M
+123.16%
Jun 30, 2025
AXA Investment Managers Paris
2.20M
2.07%
--
--
Jul 31, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Invesco NASDAQ Future Gen 200 ETF
0.6%
iShares Micro-Cap ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Russell 2000 Value ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Biotechnology ETF
0.01%
查看更多
Invesco NASDAQ Future Gen 200 ETF
占比0.6%
iShares Micro-Cap ETF
占比0.03%
Invesco Nasdaq Biotechnology ETF
占比0.02%
Avantis US Small Cap Equity ETF
占比0.02%
ProShares Ultra Nasdaq Biotechnology
占比0.02%
iShares Russell 2000 Value ETF
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
iShares Russell 2000 ETF
占比0.01%
Global X Russell 2000 ETF
占比0.01%
iShares Biotechnology ETF
占比0.01%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

MaxCyte Inc的前五大股东是谁?

MaxCyte Inc 的前五大股东如下:
Cadian Capital Management LP持有股份:8.91M,占总股份比例:8.36%。
Mirabella Financial Services LLP持有股份:6.60M,占总股份比例:6.19%。
BlackRock Institutional Trust Company, N.A.持有股份:8.21M,占总股份比例:7.70%。
The Vanguard Group, Inc.持有股份:5.60M,占总股份比例:5.25%。
River Global Investors LLP持有股份:3.25M,占总股份比例:3.05%。

MaxCyte Inc的前三大股东类型是什么?

MaxCyte Inc 的前三大股东类型分别是:
Cadian Capital Management LP
Mirabella Financial Services LLP
BlackRock Institutional Trust Company, N.A.

有多少机构持有MaxCyte Inc(MXCT)的股份?

截至2025Q3,共有287家机构持有MaxCyte Inc的股份,合计持有的股份价值约为82.96M,占公司总股份的77.85%。与2025Q2相比,机构持股有所增加,增幅为3.93%。

哪个业务部门对MaxCyte Inc的收入贡献最大?

在FY2025Q2,Product sales业务部门对MaxCyte Inc的收入贡献最大,创收5.27M,占总收入的61.94%。
KeyAI